Fig. 2: Th1/Th2-associated EBOV-GP specific antibody responses are highly affected by adjuvant formulation.
From: Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge
a Ratio of IgG2c/IgG1 EBOV-GP specific EC50 titer of sera from mice immunized with FILORAB1 unadjuvanted or with GLA-SE, SE, GLA-alum, or alum at 1 week, b 2 weeks, c 4 weeks, d 5 weeks post-immunization reported as average half-maximal effective concentration (EC50) titer (bars) determined from individual mouse serum (symbols) ELISA curves. e EBOV-GP specific IgG2c and f IgG1 specific antibody titers at 7 weeks post-immunization. g Ratio of IgG2c/IgG1 EBOV-GP specific EC50 titer at week 7. h Ratio of IgG2c/IgG1 EBOV-GP specific EC50 titers over time from 2 to 7 weeks post-immunization with each cluster representing an adjuvant group and each column of the cluster a week from 2 to 7. Error bars represent SD from the mean. Statistics are by one-way ANOVA with post hoc Tukey’s test of log-transformed EC50 titers. p > 0.1234 (ns), p < 0.0332 (*), p < 0.0021 (**), p < 0.0002 (***), p < 0.0001 (****).
